ULTRAGENYX PHARMACEUTICAL INC. (RARE) Free cash flow 2016–2025
ULTRAGENYX PHARMACEUTICAL INC. (RARE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$472.0MFY2025 · since FY2016: -$171.2M → -$472.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$472.0M | -12.1% |
| FY2024 | -$421.0M | +18.9% |
| FY2023 | -$519.0M | -4.5% |
| FY2022 | -$496.6M | -20.6% |
| FY2021 | -$411.8M | -133.8% |
| FY2020 | -$176.1M | +52.4% |
| FY2019 | -$370.2M | -25.6% |
| FY2018 | -$294.6M | -14.8% |
| FY2017 | -$256.6M | -49.9% |
| FY2016 | -$171.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RARE financial trends
RARE RevenueRARE Net incomeRARE Net marginRARE Gross profitRARE Gross marginRARE Operating incomeRARE Operating marginRARE Operating cash flowRARE Capital expendituresRARE Return on equityRARE Stock buybacksRARE Dividends paidRARE Total assetsRARE Total liabilitiesRARE Shareholders’ equityRARE overview →